AstraZeneca AstraZeneca/Merck hope for expanded ovarian cancer drug use SOLO-1 results back use in first-line maintenance therapy
Views & Analysis ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c... Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
Oncology Clovis' Rubraca close to EU approval in ovarian cancer CHMP backs conditional approval for PARP drug
News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Dexcom is first to join FDA/CMS health tech pilot The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
